Dr. Manges is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11050 Parkview Circle Dr
Fort Wayne, IN 46845Phone+1 833-724-8326Fax+1 260-425-6845
Education & Training
University of RochesterFellowship, Hematology and Medical Oncology, 1991 - 1994
Indiana University School of MedicineResidency, Internal Medicine, 1988 - 1991- Indiana University School of MedicineClass of 1988
Certifications & Licensure
IN State Medical License 1989 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
- Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
- Join now to see all
Publications & Presentations
PubMed
- 15 citationsSafety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trialGrzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas Stauffer Larsen, Krish Patel
International Journal of Hematology. 2021-11-19 - 12 citationsA phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.James R. Berenson, Robert F. Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre
American Journal of Hematology. 2017-05-01 - 59 citationsPharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Result...Jesus G. Berdeja, Sundar Jagannath, Jeffrey A. Zonder, Ashraf Badros, Jonathan L. Kaufman
Clinical Lymphoma, Myeloma & Leukemia. 2016-03-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
